IMMUNOLOGICAL MECHANISMS IN NAFLD
Article Sidebar
Main Article Content
Abstract
The pandemics of coronavirus affliction 2019 (COVID-19) and non-alcoholic roly-poly liver affliction (NAFLD) coexist. High-minded liver assistance examinations are patronise in COVID-19 and hawthorn consequence liver destruction in NAFLD, preexisting liver destruction from NAFLD hawthorn consequence the progression of COVID-19. On the other hand the prognostication appropriateness of this interaction, though, is unclear. Corpulence is a jeopardy factor for the formal propinquity of NAFLD extremely as a terrible progression of COVID-19. squadron studies communicate self-contradictory consequences with reference to the consequence of NAFLD formal propinquity on COVID-19 unwellness severity. awe-inspiring molecular similarities of cytokine pathways in both diseases, including postacute sequelae of COVID-19, indicate characteristic pathways for long-standing low-activity inflammation. This another look testament summarise existing collections with reference to the interplay of both afflictions and compare notes accomplishable contrivances of the consequence of individual affliction on the other.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19).
2.Ashmore P, Sherwood E. An overview of COVID-19 global epidemiology and discussion of potential drivers of variable global pandemic impacts. J Antimicrob Chemother. 2023;78:ii2-ii11.
3.de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, Bertoluci MC; Brazilian Diabetes Society Study Group (SBD). Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12:75.
4.Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol. 2023;29:S5-S16.
5.Moore JB. COVID-19, childhood obesity, and NAFLD: colliding pandemics. Lancet Gastroenterol Hepatol. 2022;7:499–501. doi: 10.1016/S2468-1253(22)00100-5
6.Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int. 2014;111:447–452. doi: 10.3238/arztebl.2014.0447
7.Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216–1228. doi: 10.1016/j.jhep.2019.08.005
8.Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci. 2017;18 doi: 10.3390/ijms18081649
9.Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int. 2021;15:21–35. doi: 10.1007/s12072-020-10121-2